67 -9 (83) 2025 - Kasimova S.N., Musaeva D.M. - ANTIBIOTICS: PROS AND CONS

ANTIBIOTICS: PROS AND CONS

Kasimova S.N. - Bukhara State Medical Institute named after Abu Ali ibn Sina

Musaeva D.M. - Bukhara State Medical Institute named after Abu Ali ibn Sina

Resume

This article analyzes the effectiveness of modern antibiotics, which are widely used in medicine, and examines the issues of bacterial resistance to antibiotics, their causes, and solutions to this important problem.

Keywords: antibiotics, classification, bacteria, bacterial resistance, antibiotic therapy.

First page

417

Last page

423

For citation:Kasimova S.N., Musaeva D.M. - ANTIBIOTICS: PROS AND CONS//New Day in Medicine 9(83)2025 417-423 https://newdayworldmedicine.com/en/new_day_medicine/9-83-2025

List of References

  1. Давидович Н. В., Кукалевская Наталья Николаевна, Башилова Е. Н., Бажукова Т. А. Основные принципы эволюции антибиотикорезистентности у бактерий (обзор литературы) // Клиническая лабораторная диагностика. 2020. №6. URL: https://cyberleninka.ru/article/n/osnovnye-printsipy-evolyutsii-antibiotikorezistentnosti-u-bakteriy-obzor-literatury
  2. Намазова-баранова Лейла Сеймуровна, Баранов А. А. Антибиотикорезистентность в современном мире // ПФ. 2017. №5. URL: https://cyberleninka.ru/article/n/antibiotikorezistentnost-v-sovremennom-mire
  3. Савинова Алла Анатольевна, Савицкая София Руслановна. Антибиотики польза или вред? // Проблемы Науки. 2023. №5 (183). URL: https://cyberleninka.ru/article/n/antibiotiki-polza-ili-vred (дата обращения: 18.09.2025).
  4. Список эффективных антибиотиков при простуде у взрослых. https://www.budzdorov.ru/about/news/2021/antibiotiki-pri-prostude
  5. Козлов Р.С., Голуб А.В. // Стратегия использования антимикробных препаратов как попытка ренессанса антибиотиков. //Клиническая антимикробная химиотерапия — 2011.
  6. Яковлев C.B., Довгань E.B. // Аспекты эффективности антибиотиков. // Справочник поликлинического врача— 2014.
  7. Lobanovska M, Pilla G. Penicillin's Discovery and Antibiotic Resistance: Lessons for the Future? Yale J Biol Med. 2017 Mar 29;90(1):135-145. PMID: 28356901; PMCID: PMC5369031.
  8. Wojkowska-Mach J, Godman B, Glassman A, et al. Antibiotic consumption and antimicrobial resistance in Poland; findings and implications. Antimicrob Resist Infect Control. 2018;15(7):136. doi: 10.1186/s13756-018-0428-8. PMID: 30473786; PMCID: PMC6238284
  9. Jain P, Bepari AK, Sen PK, et al. High prevalence of multiple antibiotic resistance in clinical E. coli isolates from Bangladesh and prediction of molecular resistance determinants using WGS of an XDR isolate. Sci Rep. 2021;24(11):228-59. doi: 10.1038/s41598-021-02251-w. PMID: 34819576; PMCID: PMC8613203
  10. Burlyaeva VV. Teixobactin, the first of a new class of antibiotics discovered using ichip technology. International Student Scientific Bulletin. 2019;5(2). (In Russ).
  11. Sandle T Teixobactin: A New Class of Antibiotic. SOJ Microbiol Infect Dis. 2015;3(1): 1-2. DOI: http://dx.doi.org/10.15226/ sojmid/3/1/00128
  12. Jacobsson S, Golparian D, Oxelbark J, Alirol E, Franceschi F, Gustafsson TN, Brown D, Louie A, Drusano G, Unemo M. Pharmacodynamic Evaluation of Dosing, Bacterial Kill, and Resistance Suppression for Zoliflodacin Against Neisseria gonorrhoeae in a Dynamic Hollow Fiber Infection Model. Front Pharmacol. 2021 May 21;12:682-135. doi: 10.3389/fphar.2021.682135. PMID: 34093206; PMCID: PMC8175963
  13. Bradford PA, Miller AA, O'Donnel lJ, Muller JP. Zoliflodacin: oral spiropyrimidintrione antibiotic for the treatment of neisseria gonorrhea, including multidrug-resistant isolates. ACS Infect Dis. 2020 June 12;6(6): 1332-1345. doi: 10.1021/acsinfecdis.0c00021. Epub 2020 May 12. PMID: 32329999
  14. Li P, Wei Y, Li G, Cheng H, Xu Z, Yu Z, Deng Q, Shi Y. Comparison of antimicrobial efficacy of eravacycline andtigecycline against clinical isolates of Streptococcus agalactiae in China: In vitro activity, heteroresistance, and cross-resistance. MicrobPathog. 2020 Dec; 149:104502. doi: 10.1016/j.micpath.2020.104502. Epub 2020 Sep 15. PMID: 32947016
  15. Scott LJ. Delafloxacin: a review of acute bacterial infections of the skin and skin structures. Medicines. 2020 August; 80(12):1247-1258. doi: 10.1007 /s40265-020-01358-0. Error in the section: Medicines. 2020 September; 80(14):1507. PMID: 32666425; PMCID: PMC7497496
  16. Amanda L Hurst, Kari A. Neemann, Archana Chatterjee, Chapter 55.New antibiotics. Viral, Parasitic, Bacterial, and Fungal Infections. Academic Press. 2023:675-698. ISBN 9780323857307. https://doi. org/10.1016/B978-0-323-85730-7.00036-9
  17. Since the beginning of the year. Cefiderocol: an overview of serious gram-negative bacterial infections. Medicines. 2021 September; 81(13):1559-1571. doi: 10.1007 /s40265-021-01580-4. Epub 2021 August 24. Error B: Medications. December 2021;81(18):2167. PMID: 34427896; PMCID: PMC8383240
  18. McCreary EK, Hale EL, Tamma PD. New views on antimicrobial agents: Cefiderocol. Chemotherapy of antimicrobial agents. 2021July16,;65(8):e0217120. doi: 10.1128/AAC.02171-20. Epub 2021 July 16. PMID: 34031052; PMCID: PMC8373209
  19. Gils T, Linen L, de Jong BK, Van Deun A, Dekru T. Pretomanid for the treatment of tuberculosis: a systematic review. Clinical microbiological infection. 2022 January; 28(1):31-42. doi: 10.1016 /j.cmi.2021.08.007. Epub 2021 August 14. PMID: 34400340
  20. National Center for Biotechnology Information. PubChem Compound Summary for CID 456199. Pretomanid. 2023 June29: https://pubchem.ncbi.nlm.nih.gov/compound/Pretomanid

    file

    download